Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acellular vs Whole-Cell Pertussis Vaccines in Infants
NCT00004799Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 1991
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of acellular pertussis vaccine in pertussis (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety of vaccines and Efficacy against pertussis. Started Apr 1991; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT00004799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004799.